Physician profile
Floortje Backes
NPI 1124231998
$180,705.40
in general payments reported to CMS, 2019-2025
22 companies · $23K in 2025
The $23K reported for 2025 was more than what 94% of Gynecologic Oncology providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $22K · 2021: $15K · 2022: $20K · 2023: $26K · 2024: $54K · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $74K · Travel and Lodging: $26K · Food and Beverage: $1,791 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $73,988.69 |
| Travel and Lodging | $25,620.62 |
| Food and Beverage | $1,791.27 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $39,399.17 | 2020-2024 | Jemperli, Zejula |
| Astrazeneca Pharmaceuticals Lp | $36,826.15 | 2019-2025 | Lynparza |
| Eisai INC. | $32,166.10 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $27,609.05 | 2019-2025 | Keytruda |
| Biontech Se | $20,828.06 | 2023-2025 | |
| Genmab A/S | $9,280.02 | 2025 | Tivdak |
| Genmab U.S., INC. | $3,200.00 | 2025 | Epkinly |
| Emd Serono Research & Development Institute, INC. | $2,130.00 | 2024 | |
| Clovis Oncology, INC. | $2,112.10 | 2019 | |
| Daiichi Sankyo INC. | $2,030.84 | 2023 | |
| Abbvie INC. | $1,931.80 | 2024-2025 | |
| Immunogen, INC. | $1,568.95 | 2023-2024 | Elahere, Elahere |
| Genentech USA, INC. | $1,113.91 | 2019-2020 | |
| Karyopharm Therapeutics INC. | $193.26 | 2024 | Xpovio |
| Pfizer INC. | $134.90 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tesaro, INC. | $91.00 | 2019 | |
| Tanabe Pharma America, INC. | $51.40 | 2025 | |
| Intuitive Surgical, INC. | $23.98 | 2019 | |
| Dilon Technologies, INC. | $14.71 | 2023 | Hemoblast Bellows |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Floortje Backes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.